1. Home
  2. CGEM vs NATH Comparison

CGEM vs NATH Comparison

Compare CGEM & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • NATH
  • Stock Information
  • Founded
  • CGEM 2016
  • NATH 1916
  • Country
  • CGEM United States
  • NATH United States
  • Employees
  • CGEM N/A
  • NATH N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • NATH Restaurants
  • Sector
  • CGEM Health Care
  • NATH Consumer Discretionary
  • Exchange
  • CGEM Nasdaq
  • NATH Nasdaq
  • Market Cap
  • CGEM 482.7M
  • NATH 411.9M
  • IPO Year
  • CGEM 2021
  • NATH N/A
  • Fundamental
  • Price
  • CGEM $6.45
  • NATH $108.26
  • Analyst Decision
  • CGEM Strong Buy
  • NATH
  • Analyst Count
  • CGEM 8
  • NATH 0
  • Target Price
  • CGEM $27.25
  • NATH N/A
  • AVG Volume (30 Days)
  • CGEM 525.8K
  • NATH 31.5K
  • Earning Date
  • CGEM 11-06-2025
  • NATH 11-06-2025
  • Dividend Yield
  • CGEM N/A
  • NATH 1.82%
  • EPS Growth
  • CGEM N/A
  • NATH 9.62
  • EPS
  • CGEM N/A
  • NATH 5.77
  • Revenue
  • CGEM N/A
  • NATH $150,413,000.00
  • Revenue This Year
  • CGEM N/A
  • NATH N/A
  • Revenue Next Year
  • CGEM N/A
  • NATH N/A
  • P/E Ratio
  • CGEM N/A
  • NATH $18.54
  • Revenue Growth
  • CGEM N/A
  • NATH 6.38
  • 52 Week Low
  • CGEM $6.44
  • NATH $74.60
  • 52 Week High
  • CGEM $18.62
  • NATH $118.50
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 36.01
  • NATH 56.46
  • Support Level
  • CGEM $6.44
  • NATH $103.89
  • Resistance Level
  • CGEM $7.82
  • NATH $110.95
  • Average True Range (ATR)
  • CGEM 0.43
  • NATH 2.44
  • MACD
  • CGEM -0.11
  • NATH 0.24
  • Stochastic Oscillator
  • CGEM 4.55
  • NATH 65.97

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: